Pfizer today confirmed that the first mAb biosimilar, Inflectra (infliximab), will be added to the PBS on 1 December 2015 for the treatment of eight inflammatory conditions. “Inflectra is an important therapy and we look forward to making it available to patients across Australia,”says Pfizer Australia Chairman and Managing Director David Gallagher. “Not only does
This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.